• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Karen Andersen

Karen Andersen

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  1. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  2. Will the Election Affect Earnings?

    If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.

  3. Health Care’s Latest Prognosis

    Amid a pullback, health-care companies are preparing for the next phase of the Affordable Care Act.

  4. How to Be Smarter About Risk Management

    Investors should only take risks that the market rewards--and that they can live with.

  5. Baxter's Spin-Off Strategy Is Promising

    Although 2015 may be rocky, both Baxter and Baxalta should see significant margin expansion and growth in the long term, says Morningstar's Karen Andersen .

  6. The Friday Five

    Not crushing on IPOs, Facebook's virtual strategy, a setback for Citi, and more.

  7. This Undervalued Stock Is a Global Leader

    Cost and scale advantages, as well as greater product focus in the future, are positives for this wide-moat health-care name.

  8. Gilead's Shot in the Arm

    Morningstar CEO of the Year finalist John Martin's smart capital-allocation decisions have helped drive a 100-fold increase in this biopharmaceutical's stock since he took over in 1996.

  9. A Discounted Wide Moat in Biotech

    With an improving pipeline and a new manufacturing technology, Amgen is on the path to stabilizing its moat trend.

  10. Announcing Morningstar's CEO of the Year Award Finalists

    These three CEOs have been sound stewards of shareholder capital.


©2017 Morningstar Advisor. All right reserved.